Summary
A science-based overview of modern obesity medicine—including GLP-1 and GLP-1/GIP medications, cardiovascular benefits, and new research—plus how the Couri Center’s TLC™ and Bridge Programs integrate advanced treatment with lifestyle and hormone support.
Nearly half of the global population now lives with overweight or obesity, contributing to more than 5 million deaths each year from conditions such as diabetes, cardiovascular disease, stroke, and cancer. While lifestyle changes remain foundational, the introduction of modern medical therapies—especially the GLP-1 receptor agonist semaglutide and the dual GLP-1/GIP medication tirzepatide—has been transformative in the treatment of obesity.
- Overweight and obesity now affect nearly 50% of the global population.
- Excess weight is linked to an estimated 5 million deaths each year due to complications such as diabetes, heart disease, cancer, and stroke.
- While lifestyle changes remain foundational, the introduction of novel medications—specifically the GLP-1 receptor agonist semaglutide and the dual GLP-1/GIP agonist tirzepatide—has been revolutionary in the management of obesity.
Clinical Benefits of Semaglutide and Tirzepatide
Over 68–72 weeks, clinical trials demonstrate:
- Semaglutide 2.4 mg weekly: ~15% average weight loss
- Tirzepatide 5–15 mg weekly: 15–21% average weight loss
Beyond weight reduction, both medications have demonstrated improvements in:
- Blood pressure
- Lipid profiles
- Inflammatory markers
- Physical function
- Quality of life
Cardiovascular Outcomes
The SELECT Trial, which followed more than 17,000 patients with obesity/overweight and pre-existing heart disease, showed a 20% reduction in cardiovascular death, non-fatal heart attack, and stroke with semaglutide 2.4 mg weekly over 3.3 years.
In patients with obesity and heart failure:
- Semaglutide (2.4 mg weekly for 52 weeks) improved heart failure symptoms and exercise tolerance.
- Tirzepatide significantly improved heart failure symptoms and resulted in a 38% reduction in hospitalization and cardiovascular death compared to placebo over 104 weeks.
Additional Health Benefits
- Kidney Function: In patients with type 2 diabetes and chronic kidney disease, semaglutide reduced the incidence of kidney failure by 21%.
- Sleep Apnea: A 52-week study of tirzepatide showed a reduction in apnea frequency, improving sleep quality and daytime energy.
- Metabolic Liver Disease: Tirzepatide demonstrated improvement in metabolic dysfunction–associated steatohepatitis (MASH), commonly known as fatty liver disease.
Expanding Research
- Currently, more than 200 active clinical trials are evaluating GLP-1 receptor agonists for a wide range of conditions, including obesity-related cancers, neurological disorders, cognitive impairment, and addictive behaviors.
- These medications are generally well-tolerated, with manageable side effects such as nausea, vomiting, and constipation.
- Discontinuation typically leads to weight gain, underscoring the chronic nature of obesity and the need for ongoing treatment strategies.
The Future of Obesity Medicine
- New therapies are on the horizon, including retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, which research is showing even greater efficacy than current options.
- The major challenge remains ensuring equitable access. These medications are often not covered by insurance and can be cost-prohibitive, limiting their reach despite their transformative potential.
- Orforglipron, the first oral GLP-1 agonist, is showing good results in Phase 3 studies. Patients achieved 11.2% weight loss at 72 weeks with the highest dose compared to placebo. 20% of patients who took orforglipron achieved ≥ 20% weight loss. Additional benefits included improved waist size, blood pressure, triglycerides, and cholesterol.
How the Couri Center Helps You Achieve Lasting Weight Loss
At the Couri Center, we specialize in personalized weight loss care by combining advanced medical treatment options, including the medications described above, with our proven lifestyle program, Total Lifestyle by Couri (TLC™). Our team is committed to supporting you every step of the way, empowering you to achieve lasting results and a healthier, more vibrant life.
In addition, we have created The Bridge Program, which connects (“bridges”) hormone replacement therapy (HRT) with our comprehensive weight loss approach. We find that women who are hormonally balanced often have greater success with weight management. The Bridge Program harnesses the benefits of HRT alongside our structured weight loss strategies, including nutrition counseling, lifestyle foundations, and, when appropriate, GLP-1 or GLP-1/GIP therapies. By bridging hormone balance with weight loss support, this program offers a powerful, integrative path toward optimal health and well-being.
New patients are always welcome.
Curious about medical management of obesity or lifestyle medicine? We’re here to help—new patients welcome. Schedule online through our form below or call 309-692-6838.
This article is for educational purposes only and should not be considered medical advice. Please consult your healthcare provider or schedule with the Couri Center for personalized care.
To Your Health,
Dr. Michele Couri
Dr. Michele Couri is a board-certified gynecologist, integrative medicine specialist, and Medical Director of the Couri Center, where she leads a comprehensive approach to women’s wellness, hormone health, and preventive care.
Sources
Xiang, Angie and Sumithran, Priya. Medical management of obesity: unlocking the potential. Climacteric 2025. Vol. 28, No.4, 389-393.Wharton, Sean, MD, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. NEJM. 2025 Sep 16. doi: 10.1056/NEJMoa2511774. Epub ahead of print. PMID: 40960239.